Investment Analysts’ Updated EPS Estimates for November, 11th (ACRX, AER, AGLE, AKCA, CARB, CUF.UN, DRT, IPHI, LPCN, MYOK)

Investment Analysts’ updated eps estimates for Monday, November 11th:

AcelRx Pharmaceuticals (NASDAQ:ACRX) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $2.25 target price on the stock. According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

AerCap (NYSE:AER) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “AERCAP HOLDINGS is an integrated global aviation company with a leading market position in aircraft and engine leasing, trading and parts sales.They also provides aircraft management services and performs aircraft and engine maintenance, repair and overhaul services and aircraft disassemblies through its certified repair stations. “

Aeglea Bio Therapeutics (NASDAQ:AGLE) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “

Akcea Therapeutics (NASDAQ:AKCA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company’s drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Carbonite (NASDAQ:CARB) was downgraded by analysts at William Blair from an outperform rating to a market perform rating.

Carbonite (NASDAQ:CARB) was downgraded by analysts at Lake Street Capital from a buy rating to a hold rating.

Cominar REIT (TSE:CUF.UN) was upgraded by analysts at TD Securities from a hold rating to a buy rating. TD Securities currently has C$16.00 target price on the stock, up from their previous target price of C$13.50.

Dirtt Environmental Solutions (TSE:DRT) was downgraded by analysts at National Bank Financial from an outperform rating to a sector perform rating. National Bank Financial currently has C$5.25 price target on the stock, down from their previous price target of C$7.40.

Inphi (NYSE:IPHI) had its sell rating reaffirmed by analysts at Northland Securities. The firm currently has a $45.00 target price on the stock.

Inphi (NYSE:IPHI) had its hold rating reiterated by analysts at Rosenblatt Securities.

Lipocine (NASDAQ:LPCN) was downgraded by analysts at LADENBURG THALM/SH SH from a buy rating to a neutral rating.

Lipocine (NASDAQ:LPCN) had its price target reduced by HC Wainwright from $5.00 to $2.00. HC Wainwright currently has a hold rating on the stock.

Myokardia (NASDAQ:MYOK) had its buy rating reissued by analysts at Cowen Inc. They currently have a $73.00 price target on the stock.

Power Co. of Canada (TSE:POW) was downgraded by analysts at CIBC from a neutral rating to an underperform rating. CIBC currently has C$33.00 target price on the stock, up from their previous target price of C$31.00.

Strategic Education (NASDAQ:STRA) had its buy rating reissued by analysts at Barrington Research. Barrington Research currently has a $175.00 target price on the stock.

Targa Resources (NYSE:TRGP) had its hold rating reissued by analysts at Wells Fargo & Co.

Receive News & Ratings for AcelRx Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.